Navigation Links
MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
Date:4/10/2008

SAN DIEGO, April 10 /PRNewswire/ -- MedImmune today announced that researchers will present seven abstracts on the company's oncology portfolio programs at the Annual Meeting of the American Association for Cancer Research, exemplifying the company's long-standing commitment to excellence in oncology research.

"Cancer research has long been a core area of focus at MedImmune and we are proud to share data from our increasingly large oncology portfolio at this year's meeting," said Bahija Jallal, Ph.D., vice president of translational science and head, preclinical oncology.

Investigators will present results from four studies of the novel heat shock protein 90 (Hsp90) inhibitor retaspimycin hydrochloride (also known as IPI-504); two studies of antibodies targeting the CD19 antigen, including MEDI-538 (also known as MT103); and one study of monocyte chemotactic protein-1 (MCP-1).
MedImmune research scheduled to be presented includes:

-- IPI-504, a Novel Hsp90 Inhibitor is Effective in EGFR T790M and

non-T790M Gefitinib-Resistant Lung Cancer Cell Lines (Oral

Presentation: Histone Deacetylase and Heat Shock Protein Inhibitors,

abstract 2450) - Joon O. Park, M.D., Monday, April 14 from 11:55 a.m.

- 12:10 p.m. in Room 24A-C.

-- Pharmaceutical Development of IPI-504, an Aqueous Soluble Analog of

17-AAG and Potent Inhibitor of Hsp90 (Educational Session: From

Chemistry to the Clinic: Pathways for Drug Discovery and Development

- Part 4: Chemical Development: Translating a Potent Agent into a

Registered Product) - James R. Porter, Ph.D., Saturday, April 12 from

4:15 - 4:40 p.m. in Ballroom 20D.

-- IPI-504, a Selective Inhibitor of Hsp90, Exhibits Potent Anti-Tumor

Activity Against Metastatic Melanoma Cell Lines that Harbor B-Raf or

N-Ras Mutations (Poster Session: Pharmacology and Pharmacodynamics,

abstract 4764, poster section 28, board 9) - Jon Cheesebrough, Tuesday,

April 15 from 1:00 - 5:00 p.m. in Exhibit Hall B-F.

-- IPI-504, a Selective Hsp90 Inhibitor is Biologically Active and

Tolerated in Combination with Trastuzumab in Preclinical Models of HER2

Positive Tumor Xenografts (Poster Session: Drug Discovery 2:

Combination Strategies I, abstract 4008, poster section 29, board 6)

- Ching Ching Leow, Ph.D., Tuesday, April 15 from 8:00 a.m. - 12:00

p.m. in Exhibit Hall B-F.

-- Bioavailability, Pharmacodynamic Activity, and Anti-Tumor Efficacy of

the CD19/CD3-Specific BiTE Antibody MEDI-538 (MT103) Delivered

Subcutaneously in Animal Models (Poster Session: Antibodies and

Immunotherapy, abstract 2131, poster section 23, board 6) - Kathy

Mulgrew, Monday, April 14 from 8:00 a.m. - 12:00 p.m. in Exhibit Hall

B-F.

-- Inhibition of Growth of Human Lymphoma Xenografts with a

Glycoengineered Antibody Specific for the B-Cell Antigen CD19 (Poster

Session: Antibodies and Immunotherapy, abstract 3980, poster section

28, board 8) - Beth K. Ward, Tuesday, April 15 from 8:00 a.m. - 12:00

p.m. in Exhibit Hall B-F.

-- The Characterization of a Potent, Fully Human MCP-1 Antibody In Vitro

and In Vivo (Poster Session: Antibodies, abstract 3986, poster section

28, board 14) - Z. Alexander Cao, Ph.D., Tuesday, April 15 from 8:00

a.m. - 12:00 p.m. in Exhibit Hall B-F.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on cardiovascular/gastrointestinal disease, neuroscience, oncology, infection, respiratory disease and inflammation. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
2. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
3. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
4. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
5. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
6. MedImmune Announces Seven Key Promotions and New Hires
7. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
8. MedImmune Submits Biologics License Application to FDA for Motavizumab
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. Seneca Valley High School Student Receives Science Award From MedImmune
11. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017 /PRNewswire/ - The Fight ... for Cancer Research (OICR) are pleased to report that ... A financing, with Johnson & Johnson Innovation – JJDC, ... include venture groups HealthCap, TPG Biotechnology Partners, and Genesys ... ...
(Date:2/23/2017)... Atlanta, it seems everyone has a chance to express their ... expressive and dynamic community unlike any other. The businesses that ... With their newest salon in ... on that tradition with a unique, fresh approach to head ... the newest of 13 nationwide locations, each of them well-situated ...
(Date:2/23/2017)... 2017  Imanis Life Sciences announced today the ... vaccinia viruses for virotherapy research. These viruses are ... proprietary, vaccinia virus-based technology platform for research use. ... a partnership with Genelux to offer researchers, for ... use in research," said Dr. Kah Whye ...
(Date:2/23/2017)... (PRWEB) , ... February 23, ... ... Inc., announced today that in a published evaluation of multiple immunoassay-based threat ... U.S. Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was ...
Breaking Biology Technology:
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market Intelligence ... Biometrics and Digital Identity".  Acuity characterizes 2017 as ... when increased adoption reflects a new understanding of ... "Biometrics and digital identity are often perceived ... Maxine Most , Principal of Acuity Market intelligence. ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds ... baby,s sock that monitors vital signs and alerts ... an infant,s oxygen saturation level drops. But pediatric ... alarm to parents, with no evidence of medical ... devices are marketed aggressively to parents of healthy ...
Breaking Biology News(10 mins):